Health Care & Life Sciences » Biotechnology | Mateon Therapeutics Inc.

Mateon Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,005.00
30,031.00
27,285.00
12,047.00
1,115.00
629
Other Current Assets
160.00
322.00
105.00
2,023.00
22.00
170
Total Current Assets
7,165.00
30,353.00
27,390.00
14,070.00
1,137.00
799
Net Property, Plant & Equipment
36.00
37.00
30.00
11.00
2.00
-
Intangible Assets
93.00
-
-
-
-
-
Other Assets
-
33.00
33.00
33.00
33.00
-
Total Assets
7,294.00
30,423.00
27,453.00
14,114.00
1,172.00
799
Accounts Payable
476.00
335.00
287.00
-
-
Other Current Liabilities
775.00
1,084.00
1,816.00
1,614.00
1,649.00
Total Current Liabilities
1,251.00
1,419.00
2,103.00
1,614.00
1,649.00
Total Liabilities
1,251.00
1,419.00
2,103.00
1,614.00
1,649.00
Common Equity (Total)
6,043.00
29,004.00
25,350.00
12,500.00
477.00
Total Shareholders' Equity
6,043.00
29,004.00
25,350.00
12,500.00
477.00
Total Equity
6,043.00
29,004.00
25,350.00
12,500.00
477.00
Liabilities & Shareholders' Equity
7,294.00
30,423.00
27,453.00
14,114.00
1,172.00

About Mateon Therapeutics

View Profile
Address
701 Gateway Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.mateon.com
Updated 07/08/2019
Mateon Therapeutics, Inc. operates as a clinical stage biopharmaceutical company which develops small molecule injectable drugs for the treatment of cancer. The firm develops OXi4503 for the treatment of acute myeloid leukemia. The OXi4503 has dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.